Arthritis News and Research

Latest Arthritis News and Research

Myrexis to present MPI-0485520 preclinical data at Annual Scientific Meeting

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present a poster at the 74th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP), to be held November 7-11, 2010 in Atlanta, Georgia.

7 Oct 2010

Integra Total Wrist Fusion System to be featured at ASSH Annual Meeting

Integra LifeSciences Holdings Corporation announced today that it is featuring the Integra Total Wrist Fusion System at the 65th Annual Meeting of the American Society for Surgery of the Hand (ASSH) on October 7-9, in Boston, Massachusetts.

7 Oct 2010

Chelsea Therapeutics announces underwriters exercise 1.07 million additional shares to cover over-allotments

Chelsea Therapeutics International, Ltd. has completed its previously announced public offering of common stock and announced that the underwriters exercised their option to purchase approximately 1.07 million additional shares to cover over-allotments.

7 Oct 2010

Biogen to present late-stage clinical therapies for MS at ECTRIMS Congress

Biogen Idec today announced that more than 45 company and partner-sponsored platform and poster presentations will be presented during the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Gothenburg, Sweden, October 13 - 16, 2010.

6 Oct 2010

Amgen to present oncology portfolio results at ESMO Congress

Amgen today announced that results from several important studies from the Company's ncology portfolio will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, Oct. 8-12, 2010, in Milan, Italy.

6 Oct 2010

Medtronic launches new KYPHON Express Curette for scraping or scoring bone in the spine

Medtronic Inc. today announced the launch of the new KYPHON® Express™ Curette for scraping or scoring bone in the spine, including during treatment of vertebral compression fractures with minimally invasive KYPHON® Balloon Kyphoplasty.

6 Oct 2010

CPF honors three critical areas of leadership for Pulmonary Fibrosis community

The Coalition for Pulmonary Fibrosis (CPF) has announced its annual awards honoring three critical areas of leadership that impact the work of the Pulmonary Fibrosis (PF) community.

5 Oct 2010

RHUCIN clinical trial results published in JACI journal

Santarus, Inc., a specialty biopharmaceutical company, today announced the publication of an integrated analysis of two randomized placebo-controlled clinical trials with RHUCIN (recombinant human C1 inhibitor, or rhC1INH), in the October issue of the peer reviewed Journal of Allergy and Clinical Immunology (JACI).

5 Oct 2010

Physical therapy can improve arthritis symptoms

The American College of Rheumatology is celebrating National Physical Therapy Month by encouraging people with arthritis and other rheumatic diseases to discover the benefits of rehabilitation with a physical therapist.

5 Oct 2010

Ceremed awarded NIH SBIR grant to develop soluble carrier for topical delivery of antibiotic Vancomycin

Ceremed, Inc. was awarded a Small Business Innovation Research (SBIR) grant, the company's third in a series of grants from the National Institutes of Health to develop a versatile soluble carrier with bone hemostatic properties for targeted delivery of therapeutic agents directly to surgical sites. The recently awarded grant will aid Ceremed in its effort to develop a soluble carrier to topically deliver the antibiotic Vancomycin.

5 Oct 2010

Amgen announces PRIME '203' and '181' Phase 3 trial results

Amgen today announced that results from the PRIME '203' and '181' pivotal Phase 3 trials evaluating Vectibix (panitumumab) in combination with chemotherapy (FOLFOX or FOLFIRI) as a first and second-line treatment for metastatic colorectal cancer (mCRC), respectively, were published online in the Journal of Clinical Oncology.

5 Oct 2010

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.

4 Oct 2010

Chelsea prices common stock public offering

Chelsea Therapeutics International, Ltd. announced today that it has priced a public offering of approximately 7.14 million shares of its common stock at a price of $4.90 per share which will result in gross proceeds of $35 million. Net proceeds to the company, after underwriting discounts and commissions and expenses, will be approximately $32.8 million.

1 Oct 2010

BUSM to create Center for Health Insurance Reform, Cardiovascular Outcomes and Disparities

Boston Medical Center (BMC) has been awarded a four year, $5.7 million grant from the National Heart, Lung and Blood Institute (NHLBI) for investigators from Boston University School of Medicine (BUSM) to create the Center for Health Insurance Reform, Cardiovascular Outcomes and Disparities.

1 Oct 2010

Headaches, back pain and arthritis cost companies more than $61 billion per annum

Headaches, back pain, arthritis and other aches distract employees and cost companies more than $61 billion a year in lost productive time, according to a study published in the Journal of the American Medical Association.

1 Oct 2010

Arthritis Foundation applauds House for passing bipartisan arthritis legislation

The Arthritis Foundation applauds the U.S. House of Representatives for passing the Arthritis Prevention, Control and Cure Act (H.R. 1210/S.984), the first comprehensive, bipartisan arthritis legislation in more than 30 years.

1 Oct 2010

Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases

Avila Therapeutics™, Inc., a biotechnology company developing targeted covalent drugs, announced today that it has initiated a phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of AVL-292, a novel, orally available, covalent drug that targets Bruton's tyrosine kinase (Btk). AVL-292 is the first product candidate to enter clinical evaluation from Avila's proprietary covalent drug platform, Avilomics™.

30 Sep 2010

Women's College to build Ontario's only ambulatory hospital focused on women's health

Women's College Hospital together with The Honourable Deb Matthews, Minister of Health and Long-Term Care, and women representing Ontario's diverse communities, today announced Women's College Hospital is building Ontario's only ambulatory hospital focused on meeting the unique health care needs and priorities of women.

30 Sep 2010

New online CDSMP program launched to battle against chronic illnesses

Taking the battle against the national epidemic of chronic illnesses to the Internet, the National Council on Aging (NCOA) is making Better Choices, Better Health, the online version of the internationally recognized Chronic Disease Self Management Program (CDSMP), available free for people in California and six other states Hawaii, Iowa, Maine, Massachusetts, New Jersey, and Oregon.

30 Sep 2010

NIH awards three grants to explore novel treatment strategies for muscular dystrophy

Three grants totaling more than $4.5 million, from agencies of the National Institutes of Health, will be used to explore novel treatment strategies for muscular dystrophy.

30 Sep 2010

Arthritis News and Research

Latest Arthritis News and Research

Myrexis to present MPI-0485520 preclinical data at Annual Scientific Meeting

Integra Total Wrist Fusion System to be featured at ASSH Annual Meeting

Chelsea Therapeutics announces underwriters exercise 1.07 million additional shares to cover over-allotments

Biogen to present late-stage clinical therapies for MS at ECTRIMS Congress

Amgen to present oncology portfolio results at ESMO Congress

Medtronic launches new KYPHON Express Curette for scraping or scoring bone in the spine

CPF honors three critical areas of leadership for Pulmonary Fibrosis community

RHUCIN clinical trial results published in JACI journal

Physical therapy can improve arthritis symptoms

Ceremed awarded NIH SBIR grant to develop soluble carrier for topical delivery of antibiotic Vancomycin

Amgen announces PRIME '203' and '181' Phase 3 trial results

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Chelsea prices common stock public offering

BUSM to create Center for Health Insurance Reform, Cardiovascular Outcomes and Disparities

Headaches, back pain and arthritis cost companies more than $61 billion per annum

Arthritis Foundation applauds House for passing bipartisan arthritis legislation

Avila commences AVL-292 Phase 1 clinical study for B cell cancers and autoimmune diseases

Women's College to build Ontario's only ambulatory hospital focused on women's health

New online CDSMP program launched to battle against chronic illnesses

NIH awards three grants to explore novel treatment strategies for muscular dystrophy

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Arthritis News and Research

Latest Arthritis News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in